Moreover, elevated TRIB3 expression in response to arsenic/ATRA therapy further suppressed PPARγ activity by disrupting the PPARγ/RXR dimer, which contributes to abnormal lipid metabolism in arsenic/ATRA-treated APL patients. This evidence concerns the gene PPARG and acute promyelocytic leukemia.